Education
About Us
Working with TipRanks
Follow Us
Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
Top Page
Guardian Pharmacy Services, Inc. Class A
(NYSE:GRDN)
Select Model
Select Model
Rating:68Neutral
Price Target:
$37.00
▲(12.36% Upside)
Action:DowngradedDate:03/12/26
The score is driven primarily by improving fundamentals (strong cash generation and a significantly strengthened balance sheet) and supportive technical momentum. This is tempered by a high P/E valuation and policy/operational headwinds highlighted on the earnings call (IRA impacts and some nonrecurring recent benefits).
Positive Factors
Cash generation
Consistent positive operating and free cash flow (FCF rose to about $81M in 2025) provides durable internal funding for M&A, greenfield investments and working capital needs. Strong cash conversion supports reinvestment and balance-sheet repair, improving long-term resilience despite year-to-year variability.
Balance sheet de-risking
A dramatic reduction in total debt and materially stronger equity by 2025 meaningfully lowers financial leverage and interest risk. Low net leverage increases strategic optionality to pursue disciplined M&A, absorb policy shocks, and fund operations without immediate external financing, strengthening multi‑quarter durability.
Scale & market penetration
Meaningful scale—rising residents served and strong script volume growth—drives durable demand, creates distribution leverage with long‑term care partners, and supports fixed‑cost absorption. Scale underpins improved gross profits and vaccine program economics, enhancing competitive positioning over the medium term.
Negative Factors
Regulatory pricing pressure
The Inflation Reduction Act (IRA) and related WAC reductions represent a structural revenue and pricing headwind (~$65M flagged for 2027). Mandatory price and reimbursement changes shrink addressable revenues and will require sustained margin offsetting or new services to preserve profitability over multiple years.
Earnings volatility
A sharp 2024 loss followed by a 2025 rebound highlights operating volatility tied to payor dynamics and working capital swings. Persistent earnings variability undermines predictability of cash flow and complicates multi‑period planning, increasing the risk that one adverse year could pressure liquidity or capital allocation decisions.
Acquisition / greenfield margin drag
Early‑stage acquisitions and greenfield rollouts are currently dilutive (roughly 90bp margin drag), requiring time and capital to reach profitability. Extended ramp periods and integration execution risk can depress consolidated margins and delay expected returns, testing margin sustainability over the coming quarters.
Guardian Pharmacy Services, Inc. Class A (GRDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.16B
Dividend YieldN/A
Average Volume (3M)348.83K
Price to Earnings (P/E)38.1
Beta (1Y)0.64
Revenue Growth18.68%
EPS GrowthN/A
CountryUS
Employees3,400
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.37
Shares Outstanding36,253,742
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)8.61
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.48
Enterprise Value/Gross Profit7.58
Enterprise Value/Ebitda19.22
Forecast
1Y Price Target
$37.33Price Target Upside13.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.13
Revenue Forecast (FY)$1.42B
Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model
Company DescriptionGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Guardian Pharmacy Services, Inc. Class A Earnings Call Summary
Earnings Call Date:Mar 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Positive
The call emphasized multiple strong operating and financial achievements—solid organic and reported revenue growth, meaningful adjusted EBITDA expansion, improved gross margins, strong cash generation, measurable clinical impact, and raised 2026 EBITDA guidance. Management acknowledged material industry headwinds from the IRA, one-time favorable Q4 variability, margin drag from early-stage acquisitions and greenfields, and ongoing operational complexity from new Medicare processes. Overall, the company appears to be executing well, generating cash, and positioning to offset near-term policy impacts, while remaining cautious and disciplined on M&A amid industry disruption.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Full-year 2025 reported revenue grew 18% (including acquisitions) with organic revenue growth of 13%; fourth-quarter revenue rose 17% year-over-year to $397.6M (12% organic in Q4).
Robust Adjusted EBITDA and Margin Expansion
Full-year adjusted EBITDA increased (management cited a 27% year-over-year increase with margins expanding ~50 bps to 7.9%); fourth-quarter adjusted EBITDA rose 53% year-over-year to $39.5M with a 9.9% margin.
Raised 2026 EBITDA Guidance
Company raised 2026 adjusted EBITDA guidance to $120M–$124M and maintained 2026 revenue guidance of $1.40B–$1.42B, signaling confidence in durable growth drivers and scalability.
Strong Volume and Resident Growth
Served over 205,000 residents (+10% year-over-year) and script volume increased 14% year-over-year, evidencing continued demand and operational scale.
Improved Gross Profit and Vaccine Economics
Gross profit rose 27% in Q4 to $85.5M and gross margin expanded to 21.5% from 19.8% a year ago; vaccine program contributed materially with >120,000 vaccines administered in Q3–Q4 and improved vaccine profitability (vaccine scripts +3% in Q4; 9% full-season increase).
Strong Cash Generation and Liquidity
Cash balance increased to $66M (from $5M at end of 2024), an approximate $60M increase for the year, with a reported cash conversion rate of ~60%, enabling M&A and greenfield investment.
Clinical and Economic Impact
Pharmacists performed over 100,000 clinical interventions benefiting ~74,000 residents; proactive insurance optimization produced an estimated $56M in resident cost savings, demonstrating measurable clinical and economic value.
Successful M&A and Greenfield Ramps
Three midyear acquisitions and several greenfield startups contributed to growth; Pacific Northwest acquisitions ramped faster than expected and began onboarding national accounts early, accelerating contributions.
Improved Operating Efficiency
Adjusted SG&A improved to 13% of revenue versus 13.7% a year ago, reflecting operating leverage and better labor efficiency as scale increased.
Negative Updates
IRA-Related Pricing and Operational Headwinds
The Inflation Reduction Act (IRA) introduced pricing/reimbursement pressure and operational complexity (Medicare Transaction Facilitator); management noted a material policy shift and expects additional branded drug negotiation impacts in 2027 (~$65M revenue headwind).
Nonrecurring Favorable Variability in Q4
Q4 included favorable payor dynamics and other variability that management does not expect to recur in 2026, meaning some Q4 upside may be one-time and not fully embedded in run rate.
Acquisitions and Greenfields Dampen Near-Term Margins
Recent acquisitions and greenfield startups currently reduce overall margins by approximately 90 basis points as some locations remain early in their path to profitability.
Industry Disruption and Competitive Stress
The industry is under pressure (including a peer bankruptcy referenced), increasing uncertainty; consolidation and operator divestitures create both risk and opportunity but also operational continuity challenges.
Branded Inhaler/Policy Headwind
Management cited a branded inhaler category headwind (an unintended consequence of prior legislation), which negatively affected performance and required navigation during 2025.
Stock-Based Compensation and Expense Step-Up
Following new LTIP grants, stock-based compensation is expected to increase to a quarterly run rate of approximately $3.0M in 2026 (up from ~ $1.0M in the quarter when pre-IPO program sunset), increasing operating expenses.
Uncertainty Around M&A Pace and Market Dynamics
While the M&A pipeline is described as robust, management emphasized a disciplined approach given industry change; potential opportunities from distressed peers are uncertain and timing is unclear.
Company Guidance
Management raised 2026 adjusted EBITDA guidance to $120–$124 million (building on a $115 million adjusted EBITDA in 2025 and an exit-2025 run rate of about $110 million) while maintaining revenue guidance of $1.40–$1.42 billion, implying an adjusted EBITDA margin near ~8.6% at the midpoint; they said quarterly revenue/EBITDA cadence should resemble 2025 with vaccine seasonality weighted to Q4. For 2026 they expect D&A of roughly $21 million, stock‑based compensation to step up to about $3 million per quarter, an effective tax rate near 26%, and they do not include future acquisitions in the outlook; they also excluded the one‑time favorable Q4 variability from the base and said they expect to offset the IRA’s 2026 EBITDA impact. Looking further out, management flagged an estimated ~$65 million revenue headwind from additional branded drug negotiations in 2027.Guardian Pharmacy Services, Inc. Class A Financial Statement Overview
Summary
Strong multi-year revenue expansion and consistently positive free cash flow, plus a materially de-risked 2025 balance sheet with debt reduced sharply. The key offset is earnings volatility (notably the 2024 loss versus the 2025 rebound), which raises questions about net-margin durability.Income Statement
Revenue has scaled steadily from $736M (2020) to $1.45B (2025), with generally healthy growth through 2023 before a sharp slowdown in 2024 and re-acceleration in 2025. Profitability is mixed: gross margin has been stable around ~20%, but 2024 saw a meaningful loss (negative net margin) followed by a solid rebound in 2025 to a ~3.4% net margin. Overall, the business shows good top-line momentum and margin stability at the gross level, but the 2024 earnings drawdown raises questions about operating volatility and cost control consistency.63
Positive
Balance Sheet
Leverage has improved dramatically: total debt declined from ~$69M (2023) to ~$7M (2025), and debt relative to equity moved from elevated levels in 2021–2023 to very low in 2025. Equity also expanded sharply by 2025, supporting a stronger capital base. The main negative is the recent profitability whiplash (large loss in 2024) which can pressure balance-sheet quality if repeated, but as of 2025 the balance sheet screens conservative and meaningfully de-risked versus prior years.70
Positive
Cash Flow
Cash generation is a clear strength: operating cash flow and free cash flow are positive across all years shown, with 2025 free cash flow rising to ~$81M and showing strong growth versus 2024. Cash conversion appears solid with free cash flow running at a high proportion of net income in profitable years, supporting earnings quality. The key watch item is variability—free cash flow dipped in 2022 and 2024 before rebounding—suggesting working-capital or spending swings that can make year-to-year cash performance less predictable.74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.45B | 1.23B | 1.05B | 908.91M | 792.07M |
| Gross Profit | 282.04M | 244.37M | 208.31M | 185.87M | 161.26M |
| EBITDA | 111.25M | -43.43M | 58.81M | 68.15M | 46.49M |
| Net Income | 49.22M | -87.29M | 23.90M | 35.42M | 16.31M |
Balance Sheet | |||||
| Total Assets | 412.66M | 320.81M | 271.17M | 256.11M | 235.85M |
| Cash, Cash Equivalents and Short-Term Investments | 65.62M | 4.66M | 752.00K | 607.00K | 15.01M |
| Total Debt | 44.72M | 37.33M | 69.15M | 62.98M | 55.04M |
| Total Liabilities | 194.73M | 170.83M | 211.31M | 180.18M | 182.53M |
| Stockholders Equity | 217.92M | 142.67M | 28.21M | 42.73M | 23.93M |
Cash Flow | |||||
| Free Cash Flow | 80.71M | 41.59M | 56.26M | 31.75M | 49.22M |
| Operating Cash Flow | 100.29M | 57.96M | 70.82M | 48.52M | 58.50M |
| Investing Cash Flow | -32.26M | -30.41M | -13.44M | -17.90M | -13.15M |
| Financing Cash Flow | -7.07M | -23.64M | -57.23M | -45.03M | -36.79M |
Guardian Pharmacy Services, Inc. Class A Technical Analysis
Positive
32.93
Price Trends
31.98
Positive
30.71
Positive
26.95
Positive
Market Momentum
0.24
Positive
50.39
Neutral
43.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRDN, the sentiment is Positive. The current price of 32.93 is below the 20-day moving average (MA) of 33.19, above the 50-day MA of 31.98, and above the 200-day MA of 26.95, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 50.39 is Neutral, neither overbought nor oversold. The STOCH value of 43.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRDN.
Guardian Pharmacy Services, Inc. Class A Risk Analysis
Guardian Pharmacy Services, Inc. Class A disclosed 42 risk factors in its most recent earnings report. Guardian Pharmacy Services, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Guardian Pharmacy Services, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $115.37B | 21.30 | -245.27% | 0.37% | 17.23% | 66.17% | |
73 Outperform | $50.91B | 25.74 | -58.93% | 0.98% | 4.37% | 28.48% | |
68 Neutral | $2.16B | 38.14 | 25.85% | ― | 18.68% | ― | |
65 Neutral | $8.59B | 23.11 | 11.39% | ― | 3.51% | 29.65% | |
61 Neutral | $65.11B | 29.30 | 101.43% | 0.66% | 9.31% | 5.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GRDN
Guardian Pharmacy Services, Inc. Class A
34.09
12.89
60.80%
COR
Cencora
334.71
72.45
27.63%
CAH
Cardinal Health
216.36
86.53
66.65%
HSIC
Henry Schein
74.87
2.87
3.99%
MCK
McKesson
941.89
282.89
42.93%
Guardian Pharmacy Services, Inc. Class A Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Guardian Pharmacy Reaffirms 2025 Outlook, Issues 2026 Guidance
Positive
Jan 13, 2026
Guardian Pharmacy Services, a major U.S. long-term care pharmacy operator, reaffirmed its 2025 revenue guidance of $1.43 billion to $1.45 billion and adjusted EBITDA guidance of $104 million to $106 million, while issuing an initial 2026 outlook that anticipates revenue of $1.40 billion to $1.42 billion after the impact of Inflation Reduction Act drug-pricing reforms and wholesale acquisition cost reductions. Despite the expected top-line pressure from these mandatory pricing changes, the company projects 2026 adjusted EBITDA of $115 million to $118 million—about 11% year-on-year growth and implying an adjusted EBITDA margin above 8%—and highlighted that its strengthened operating model should allow it to maintain its low double-digit adjusted EBITDA growth trajectory without altering its approach to resident care or facility support; Guardian also disclosed it had completed the year-end acquisition of a single pharmacy in Montana, extending its geographic footprint into a new territory in line with its expansion strategy.
The most recent analyst rating on (GRDN) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Guardian Pharmacy Services, Inc. Class A stock, see the GRDN Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.